The effect of betahistine mesylate on cognitive function for patients with peripheral vestibular dysfunction.
- Conditions
- Peripheral Vestibular Dysfunction
- Registration Number
- JPRN-jRCT1031210699
- Lead Sponsor
- Kobayashi Sei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
1) Patients diagnosed with vertigo at department of Otorhinolaryngology, Showa University Fujigaoka Hospital.
2) Patients diagnosed with mild cognitive impairment or suspected dementia , and MMSE score is 26 points or less.
3) Patients aged 20 years or older at the time of obtaining consent.
4) Patients who consented to participate in this study.
1) Patients who are contraindicated for the administration of betahistine mesylate.
2) Patients who have taken betahistine mesylate within the past month from the first visit.
3) Patients with MMSE score of 21 points or less and suspected dementia who meet the dementia diagnostic criteria (DSM-5 (2013)) and should prioritize their treatment.
4) Patients with malignant tumors.
5) Patients suffering from severe liver dysfunction, renal dysfunction, or heart disease that affect drug safety assessment.
6) Patients with a history of cerebrovascular accident.
7) Patients judged by the investigator to be ineligible for research.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in Benton Visual Retention Test (BVRT) scores before and 12 weeks after the start of treatment between the betahistine mesylate-treated group and the non-treated group.
- Secondary Outcome Measures
Name Time Method Differences in Mini Mental State Examination score, Trail Making Test score, and VSRAD Z score before and 12 weeks after the start of treatment between the betahistine mesylate-treated group and the non-treated group.